NEW YORK, Jan. 06, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of TG Therapeutics, Inc. (“TGTX”) (NASDAQ:TGTX) between September 15, 2014 and October 12, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of New York. To get more information go to:
http://www.zlk.com/pslra/tg-therapeutics
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that, throughout the Class Period, TGTX misrepresented and/or omitted material information concerning its GENUINE Phase III clinical trial for its proprietary combination of drug therapies TG-1101 and TGR-1202. The Phase III trial consisted of two parts, Part I evaluating the effect of the addition of TG-1101 to ibrutinib on overall response rate (ORR) in approximately 200 patients, and Part II evaluating the effect of the addition of TG-1101 to ibrutinib on progression-free survival (PFS) in all study patients.
During the class period TGTX repeatedly assured investors as to the efficacy and potential FDA approval of the treatment, referring to it as a “best-in-class treatment.” Then on October 13, 2016, TGTX announced that it would abandon Part II of the study, thus annulling its filed Special Protocol Assessment with the FDA and cutting enrollment and increasing the likelihood that the FDA would not approve the combination treatment.
If you suffered a loss in TGTX you have until March 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 



